Literature DB >> 19319061

Definitive treatment of persistent frontal sinus infections: elimination of dead space and sinonasal communication.

Eduardo D Rodriguez1, Matthew G Stanwix, Arthur J Nam, Hugo St Hilaire, Oliver P Simmons, Paul N Manson.   

Abstract

BACKGROUND: Frontal sinus injury involving nasofrontal outflow tract obstruction is routinely managed by obliteration or cranialization; however, a small percentage of patients develop persistent indolent infections despite routine measures. The authors discuss the course of persistent infection following frontal sinus fractures and propose a novel treatment that definitively obliterates and separates the nasofrontal outflow tract from the cranium in these patients.
METHODS: Seven consecutive patients with persistent indolent infections associated with frontal sinus fractures were identified and treated at the R Adams Cowley Shock Trauma Center and The Johns Hopkins Hospital from 2005 to 2008.
RESULTS: There were three women and four men, with an average age of 41 years. Injury resulted from motor vehicle crashes (n = 4), motorcycle crash (n = 1), fall (n = 1), and other accident (n = 1). All patients were previously treated with conventional techniques (average, 3.6 procedures and 11 years from initial injury) and prolonged antibiotic therapy without resolution of symptoms. Definitive treatment included radical débridement and obliteration with a free fibula flap in a single stage. All flaps survived and resulted in complete sinonasal separation and eradication of infection. There were no donor-site or frontal sinus complications.
CONCLUSIONS: Radical débridement, meticulous removal of the tenacious sinus mucosa, and reconstruction with a free fibular flap in a single stage is a superb choice for eliminating persistent infectious complications associated with frontal sinus fractures in patients who have failed conventional management. The fibular flap provides a secure horizontal buttress, seals the nasofrontal outflow tract with vascularized muscle, and obliterates dead space.

Entities:  

Mesh:

Year:  2009        PMID: 19319061     DOI: 10.1097/PRS.0b013e318199f4cd

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  7 in total

1.  Frontal sinus obliteration with iliac crest bone grafts. Review of 8 cases.

Authors:  Marcelo Monnazzi; Marisa Gabrielli; Valfrido Pereira-Filho; Eduardo Hochuli-Vieira; Henrique de Oliveira; Mario Gabrielli
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2014-06-12

Review 2.  Trauma of the midface.

Authors:  Thomas S Kühnel; Torsten E Reichert
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

3.  Reconstructive Management of Gunshot Wounds to the Frontal Sinus: An Urban Trauma Center's Perspective.

Authors:  Edgar Soto; Alyssa K Ovaitt; Ashlynn R Clark; Rachel R Tindal; Katherine F Chiasson; Zain Aryanpour; Shivani Ananthasekar; John H Grant; René P Myers
Journal:  Ann Plast Surg       Date:  2021-06-01       Impact factor: 1.763

Review 4.  Frontal Sinus Fractures: Evidence and Clinical Reflections.

Authors:  Christopher D Lopez; Ricardo Rodriguez Colon; Joseph Lopez; Paul N Manson; Eduardo D Rodriguez
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-04-18

5.  Comparison of Postoperative Surgical-Site Infection and Symptomatic Intracranial Hemorrhage between Staged and Simultaneous Cranioplasty with Ventriculoperitoneal Shunt Placement: A Meta-Analysis.

Authors:  Hoonkyo Jung; Kyoung Min Jang; Hyun Ho Choi; Taek Kyun Nam; Yong-Sook Park; Jeong-Taik Kwon
Journal:  Korean J Neurotrauma       Date:  2020-05-26

6.  Modified cranialization and secondary cranioplasty for frontal sinus infection after craniotomy: technical note.

Authors:  Nobutaka Yoshioka
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-08-27       Impact factor: 1.742

7.  Warfare-related secondary anterior cranioplasty.

Authors:  Ali Ebrahimi; Nasrin Nejadsarvari; Hamid Reza Rasouli; Azin Ebrahimi
Journal:  Ann Maxillofac Surg       Date:  2016 Jan-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.